LON:SCLP Scancell Share Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Scancell Holdings plc Please log in to your account or sign up in order to add this asset to your watchlist. GBX 13.28 -0.47 (-3.42%) (As of 06/27/2022 12:06 PM ET) Add Compare Share Today's Range 13.28▼ 13.7550-Day Range 12.10▼ 17.2052-Week Range 10.50▼ 23.90Volume257,408 shsAverage Volume786,482 shsMarket Capitalization£108.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsEarningsInsider TradesHeadlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SCLP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scancell and its competitors with MarketBeat's FREE daily newsletter. Email Address SCLP Stock Forecast (MarketRank)Overall MarketRank™0.99 out of 5 starsAnalyst Opinion: 0.0Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Scancell. Previous Next 4.9 Community Rank Outperform VotesScancell has received 187 “outperform” votes. (Add your “outperform” vote.)Underperform VotesScancell has received 64 “underperform” votes. (Add your “underperform” vote.)Community SentimentScancell has received 74.50% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Scancell and other stocks. Vote “Outperform” if you believe SCLP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SCLP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldScancell does not currently pay a dividend.Dividend GrowthScancell does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Scancell insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Scancell is -13.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Scancell is -13.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioScancell has a P/B Ratio of 4.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Scancell (LON:SCLP)Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.Read More SCLP Stock News HeadlinesJune 23, 2022 | proactiveinvestors.comScancell targets emerging class of cancer treatment with latest addition to pipelineJune 23, 2022 | americanbankingnews.comScancell (LON:SCLP) Shares Cross Below 200-Day Moving Average of $15.44June 16, 2022 | proactiveinvestors.comScancell Holdings expands its phase II trial of cancer drug SCIB1June 15, 2022 | morningstar.comFTSE 100 Seen Higher With Fed Rate Decision In Focus - MorningstarJune 15, 2022 | proactiveinvestors.comProactive news headlines: Scancell, Faron, Oracle Power, Net Scientific and more - Proactive Investors USAJune 15, 2022 | proactiveinvestors.comScancell Holdings expands phase II trial of cancer drug SCIB1 - Proactive Investors USAJune 14, 2022 | proactiveinvestors.comScancell Holdings" CEO Lindy Durrant updates after treating first patient with cancer vaccine - Proactive Investors USAJune 13, 2022 | morningstar.co.ukIN BRIEF: Scancell says first patient dosed in Modi-1 trial for cancer - MorningstarJune 13, 2022 | proactiveinvestors.comScancell treats first patient with Modi-1 cancer vaccineMay 17, 2022 | streetinsider.comNet Asset Value(s) - StreetInsider.comApril 23, 2022 | fool.co.ukThese are the top trending stocks in the UK right nowMarch 29, 2022 | proactiveinvestors.comScancell says South African authorities have signed off a broadening of its Covid study - Proactive Investors USAMarch 29, 2022 | marketwatch.comScancell Holdings Says South Africa Broadens Covidity Phase 1 Clinical Trial - MarketWatchSee More Headlines Industry, Sector and Symbol Stock ExchangeLON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:SCLP CUSIPN/A CIKN/A Webwww.scancell.co.uk Phone+44-115-8231863FaxN/AEmployees25Year FoundedN/ACompany Calendar Last Earnings1/31/2020Today6/27/2022Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio35.11 Current Ratio24.05 Quick Ratio24.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 4.06 per share Price / Cash Flow3.27 Book ValueGBX 2.80 per share Price / Book4.74Miscellaneous Outstanding Shares815,219,000Free FloatN/AMarket Cap£108.26 million OptionableNot Optionable BetaN/A Scancell Frequently Asked Questions How has Scancell's stock performed in 2022? Scancell's stock was trading at GBX 20 at the start of the year. Since then, SCLP stock has decreased by 33.6% and is now trading at GBX 13.28. View the best growth stocks for 2022 here. How were Scancell's earnings last quarter? Scancell Holdings plc (LON:SCLP) announced its quarterly earnings data on Friday, January, 31st. The company reported ($0.56) EPS for the quarter. View Scancell's earnings history. Who are Scancell's key executives? Scancell's management team includes the following people: Prof. Lindy Gillian Durrant Ph.D., Founder, CEO, Chief Scientific Officer & DirectorDr. Richard Morley Goodfellow Ph.D., Interim Chief Bus. Officer & Non-Exec. DirectorDr. Sally Elizabeth Adams, Chief Devel. Officer & Director (Age 61, Pay $258.29k)Mr. Keith Green, Director of Fin. & Admin. and Company Sec.Dr. Samantha Paston Ph.D., Head of Translational ResearchDr. Adrian Parry Ph.D., Head of ManufacturingMs. Akua Asare, Head of QualityMr. Fayaz Master, Head of Clinical Operations Who are some of Scancell's key competitors? Some companies that are related to Scancell include Dyne Therapeutics (DYN), ProMetic Life Sciences (PLI), Horizon Discovery Group plc (HZD.L) (HZD), Precigen (PGEN), Theratechnologies (TH), Inventiva (IVA), VIVO Cannabis (ABCN), Emblem (EMC), Verona Pharma plc (VRP.L) (VRP), Vor Biopharma (VOR), Redx Pharma (REDX), Fennec Pharmaceuticals (FRX), Bioventix (BVXP), BriaCell Therapeutics (BCT) and Agronomics (ANIC). View all of SCLP's competitors. What other stocks do shareholders of Scancell own? Based on aggregate information from My MarketBeat watchlists, some companies that other Scancell investors own include KAZ Minerals (KAZ), Standard Chartered (STAN), Petropavlovsk (POG), AorTech International (AOR), Ascential (ASCL), Advanced Oncotherapy (AVO), Empyrean Energy (EME), Lloyds Banking Group (LYG), Aminex (AEX) and Sound Energy (SOU). What is Scancell's stock symbol? Scancell trades on the London Stock Exchange (LON) under the ticker symbol "SCLP." How do I buy shares of Scancell? Shares of SCLP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Scancell's stock price today? One share of SCLP stock can currently be purchased for approximately GBX 13.28. How much money does Scancell make? Scancell (LON:SCLP) has a market capitalization of £108.26 million. How many employees does Scancell have? Scancell employs 25 workers across the globe. How can I contact Scancell? Scancell's mailing address is Department of Clinical Oncology Hucknall Road, NOTTINGHAM, NG5 1PB, United Kingdom. The official website for Scancell is www.scancell.co.uk. The company can be reached via phone at +44-115-8231863. This page (LON:SCLP) was last updated on 6/27/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
